Chaplin P J, De Rose R, Boyle J S, McWaters P, Kelly J, Tennent J M, Lew A M, Scheerlinck J P
Cooperative Research Centre for Vaccine Technology Unit, CSIRO Animal Health, Parkville, Victoria 3052, Australia.
Infect Immun. 1999 Dec;67(12):6434-8. doi: 10.1128/IAI.67.12.6434-6438.1999.
A large-scale DNA vaccination trial was performed with sheep to investigate whether an antigen targeted by CTLA-4 enhanced and accelerated the humoral immune response. Vaccination with genetically detoxified phospholipase D (DeltaPLD) has been shown to be effective, at least partially, against Corynebacterium pseudotuberculosis, the causal agent of caseous lymphadenitis in sheep. CTLA-4 binds to B7 on antigen-presenting cells and thus was used to direct the fusion antigens to sites of immune induction. Here we demonstrated that targeting DeltaPLD as a CTLA-4 fusion protein significantly enhanced the speed, magnitude, and longevity of the antibody response compared to that obtained with DNA encoding DeltaPLD. While all groups of sheep vaccinated with DNA encoding DeltaPLD were afforded better protection against an experimental challenge with C. pseudotuberculosis than those immunized with an irrelevant plasmid or those left unimmunized, the best protection was provided by the targeted DNA vaccine. We propose that targeting antigens to antigen-presenting cells offers a generic strategy for enhancing the efficacy of DNA vaccines.
用绵羊进行了一项大规模DNA疫苗接种试验,以研究细胞毒性T淋巴细胞相关抗原4(CTLA-4)靶向的抗原是否能增强并加速体液免疫反应。已证明用基因解毒的磷脂酶D(DeltaPLD)进行疫苗接种至少部分有效地对抗绵羊干酪性淋巴结炎的病原体——伪结核棒状杆菌。CTLA-4与抗原呈递细胞上的B7结合,因此被用于将融合抗原引导至免疫诱导部位。在此我们证明,与用编码DeltaPLD的DNA所获得的结果相比,将DeltaPLD作为CTLA-4融合蛋白进行靶向显著提高了抗体反应的速度、强度和持久性。虽然所有接种编码DeltaPLD的DNA的绵羊组比用无关质粒免疫的绵羊组或未免疫的绵羊组在抵抗伪结核棒状杆菌的实验攻击方面获得了更好的保护,但靶向DNA疫苗提供了最佳保护。我们提出,将抗原靶向抗原呈递细胞为提高DNA疫苗的效力提供了一种通用策略。